摘要:
The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
摘要:
A multiplex transmission system includes a number of multiplex transmission devices connected to each other via a common transmission line for transmitting frames of data. Each frame of data includes a string of bits. The number of multiplex transmission devices includes a first multiplex transmission device having a first communication controller, the first communication controller transmitting a first frame of data at predetermined intervals of time while changing a predetermined bit of data in the first frame; and a second multiplex transmission device having a second communication controller, the second communication controller transmitting a second frame of data to the first multiplex transmission device in response to one of (i) a change in input data from an external equipment, and (ii) a change in the predetermined bit of the first frame when the first frame is received by the second multiplex transmission device from the first multiplex transmission device.
摘要:
A terminal node (40); which includes a first bias unit (41) for biasing a first transmission line (10), out of two common transmission lines (10, 11), to a power supply potential, a second bias unit (42) for biasing a second transmission line (11) to the ground potential, and a communication control unit (43) for controlling data transmission. Another terminal node (50), which includes a communication control unit (51) is also provided. Connecting terminals (44 to 47, 52 to 55) are provided which connect the bias units (41, 42) and the communication control units (43, 51) of the terminal nodes (40, 50) to the transmission lines (10, 11) at two points for each line, and the terminal nodes (40, 50) are daisy-chain-connected to the transmission lines (10, 11) by means of the connecting terminals.